Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Leflon-Guibout, V.
Right arrow Articles by Nicolas-Chanoine, M.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leflon-Guibout, V.
Right arrow Articles by Nicolas-Chanoine, M.-H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 367-371
© 2002 The British Society for Antimicrobial Chemotherapy

Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection

Véronique Leflon-Guibout, Géraldine Ternat, Beate Heym and Marie-Hélène Nicolas-Chanoine,*

Microbiology Department, Hôpital Ambroise Paré, AP-HP, and Faculté Paris-Ouest, Université Paris V, France

The objective of the study was to define whether individual exposure to co-amoxiclav is a risk factor for selecting co-amoxiclav-resistant Escherichia coli in vivo. One hundred and eight patients were included in our study as soon as they were found to have a urinary tract infection (UTI) due to E. coli. Stool probes were also undertaken for some of these patients. Co-amoxiclav administration in the month before diagnosing the UTI, and any treatment to cure the current UTI were recorded for all patients. When co-amoxiclav-resistant E. coli was detected in the stools after diagnosis of E. coli UTI, isolates were compared with urinary E. coli isolates in terms of clonal relatedness, ß-lactam susceptibility and mechanisms of ß-lactam resistance. The patients who had taken co-amoxiclav in the month before the reported E. coli UTI had a significantly higher risk of being infected with co-amoxiclav-resistant E. coli. Those patients treated with amoxicillin for a current infection were at greater risk of intestinal carriage of co-amoxiclav-resistant E. coli; those treated with co-amoxiclav had a greater risk of intestinal carriage of co-amoxiclav-resistant Gram-negative bacilli than patients treated with third-generation cephalosporins or fluoroquinolones. Hence, individual exposure to co-amoxiclav is a risk factor for UTIs caused by co-amoxiclav-resistant E. coli or for carrying co-amoxiclav-resistant Gram-negative bacilli in the digestive tract.

* Correspondence address. Microbiology Department, Hôpital A. Paré, 9 avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France. Tel: +33-1-49-09-55-40; Fax: +33-1-49-09-59-21; E-mail: marie-helene.nicolas-chanoine{at}apr.ap-hop-paris.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
S. Hillier, Z. Roberts, F. Dunstan, C. Butler, A. Howard, and S. Palmer
Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study
J. Antimicrob. Chemother., July 1, 2007; 60(1): 92 - 99.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
T. M. Hooton, D. Scholes, K. Gupta, A. E. Stapleton, P. L. Roberts, and W. E. Stamm
Amoxicillin-Clavulanate vs Ciprofloxacin for the Treatment of Uncomplicated Cystitis in Women: A Randomized Trial
JAMA, February 23, 2005; 293(8): 949 - 955.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Leflon-Guibout, C. Jurand, S. Bonacorsi, F. Espinasse, M. C. Guelfi, F. Duportail, B. Heym, E. Bingen, and M.-H. Nicolas-Chanoine
Emergence and Spread of Three Clonally Related Virulent Isolates of CTX-M-15-Producing Escherichia coli with Variable Resistance to Aminoglycosides and Tetracycline in a French Geriatric Hospital
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3736 - 3742.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Westman, S. Lundin, A. Hermansson, and A. Melhus
{beta}-Lactamase-Producing Nontypeable Haemophilus influenzae Fails To Protect Streptococcus pneumoniae from Amoxicillin during Experimental Acute Otitis Media
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3536 - 3542.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Sommet, C. Sermet, P. Y. Boelle, M. Tafflet, C. Bernede, and D. Guillemot
No significant decrease in antibiotic use from 1992 to 2000, in the French community
J. Antimicrob. Chemother., August 1, 2004; 54(2): 524 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. S. Kaye, H. S. Gold, M. J. Schwaber, L. Venkataraman, Y. Qi, P. C. De Girolami, M. H. Samore, G. Anderson, J. K. Rasheed, and F. C. Tenover
Variety of {beta}-Lactamases Produced by Amoxicillin-Clavulanate-Resistant Escherichia coli Isolated in the Northeastern United States
Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1520 - 1525.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.